Detalhe da pesquisa
1.
By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
J Virol
; 93(11)2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30918073
2.
Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy.
J Virol
; 88(10): 5242-55, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24574403
3.
Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination.
Clin Transl Immunology
; 11(5): e1392, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35573979
4.
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-ßGal and MVA-MUC1 (TG4010) in a murine tumor model.
Hum Vaccin Immunother
; 14(1): 140-145, 2018 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28925793
5.
Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors.
Vaccine
; 35(4): 577-585, 2017 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28012777
6.
Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.
Oncoimmunology
; 5(2): e1080414, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27057460
7.
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.
Oncoimmunology
; 5(10): e1220467, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27853644
8.
Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein.
Clin Vaccine Immunol
; 21(2): 147-55, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24307238